CD40LG and plasma cell myeloma: Lenalidomide has been shown to inhibit IgM antibody synthesis both in vitro [20] and in IgM multiple myeloma [21], and we have observed marked clinical improvements in rituximab‐refractory anti‐MAG neuropathy patients treated with lenalidomide.